This Article  • Full text  • PDF  • Corrected PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (299)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Surgical Interventions  • Cardiovascular/ Cardiothoracic Surgery  • Vascular Surgery  • Randomized Controlled Trial  • Cardiovascular Intervention  • Revascularization  • Thrombolysis  • Alert me on articles by topic

REPLACE-2 Randomized Trial

A. Michael Lincoff, MD; John A. Bittl, MD; Robert A. Harrington, MD; Frederick Feit, MD; Neal S. Kleiman, MD; J. Daniel Jackman, MD; Ian J. Sarembock, MD; David J. Cohen, MD; Douglas Spriggs, MD; Ramin Ebrahimi, MD; Gadi Keren, MD; Jeffrey Carr, MD; Eric A. Cohen, MD; Amadeo Betriu, MD; Walter Desmet, MD; Dean J. Kereiakes, MD; Wolfgang Rutsch, MD; Robert G. Wilcox, MD; Pim J. de Feyter, MD; Alec Vahanian, MD; Eric J. Topol, MD; for the REPLACE-2 Investigators

JAMA. 2003;289:853-863.

Context  The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during contemporary percutaneous coronary intervention (PCI).

Objective  To determine the efficacy of bivalirudin, with glycoprotein IIb/IIIa (Gp IIb/IIIa) inhibition on a provisional basis for complications during PCI, compared with heparin plus planned Gp IIb/IIIa blockade with regard to protection from periprocedural ischemic and hemorrhagic complications.

Design, Setting, and Participants  The Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)–2 trial, a randomized, double-blind, active-controlled trial conducted among 6010 patients undergoing urgent or elective PCI at 233 community or referral hospitals in 9 countries from October 2001 through August 2002.

Interventions  Patients were randomly assigned to receive intravenous bivalirudin (0.75-mg/kg bolus plus 1.75 mg/kg per hour for the duration of PCI), with provisional Gp IIb/IIIa inhibition (n = 2999), or heparin (65-U/kg bolus) with planned Gp IIb/IIIa inhibition (abciximab or eptifibatide) (n = 3011). Both groups received daily aspirin and a thienopyridine for at least 30 days after PCI.

Main Outcome Measures  The primary composite end point was 30-day incidence of death, myocardial infarction, urgent repeat revascularization, or in-hospital major bleeding; the secondary composite end point was 30-day incidence of death, myocardial infarction, or urgent repeat revascularization.

Results  Provisional Gp IIb/IIIa blockade was administered to 7.2% of patients in the bivalirudin group. By 30 days, the primary composite end point had occurred among 9.2% of patients in the bivalirudin group vs 10.0% of patients in the heparin-plus-Gp IIb/IIIa group (odds ratio, 0.92; 95% confidence interval, 0.77-1.09; P = .32). The secondary composite end point occurred in 7.6% of patients in the bivalirudin vs 7.1% of patients in the heparin-plus-Gp IIb/IIIa groups (odds ratio, 1.09; 95% confidence interval 0.90-1.32; P = .40). Prespecified statistical criteria for noninferiority to heparin plus Gp IIb/IIIa were satisfied for both end points. In-hospital major bleeding rates were significantly reduced by bivalirudin (2.4% vs 4.1%; P<.001).

Conclusions  Bivalirudin with provisional Gp IIb/IIIa blockade is statistically not inferior to heparin plus planned Gp IIb/IIIa blockade during contemporary PCI with regard to suppression of acute ischemic end points and is associated with less bleeding.

Author Affiliations: Cleveland Clinic Foundation, Cleveland, Ohio (Drs Lincoff and Topol); Ocala Heart Institute, Munroe Regional Medical Center, Ocala, Fla (Dr Bittl); Duke Clinical Research Institute, Durham, NC (Dr Harrington); New York University School of Medicine, New York (Dr Feit); Baylor College of Medicine and Methodist Hospital, Houston, Tex (Dr Kleiman); Tyler Cardiovascular Consultants/Trinity Mother Frances Hospital, Tex (Dr Jackman); University of Virginia Health System, Charlottesville (Dr Sarembock); Beth Israel Deaconess Medical Center, Boston, Mass (Dr D. Cohen); Clearwater Cardiovascular Consultants, Clearwater, Fla (Dr Spriggs); West Los Angeles VA, Los Angeles, Calif (Dr Ebrahimi); Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (Dr Keren); East Texas Medical Center, Tyler (Dr Carr); Sunnybrook & Women's College Health Sciences Center, Toronto, Ontario (Dr E. Cohen); University of Barcelona Hospital Clinic, Barcelona, Spain (Dr Betriu); University Hospital Gasthuisberg, Leuven, Belgium (Dr Desmet); the Lindner Center, Ohio Heart Health Center, Cincinnati (Dr Kereiakes); University Clinic Charite Berlin, Berlin, Germany (Dr Rutsch); University Hospital Nottingham, Nottingham, England (Dr Wilcox); University Hospital Dijkzigt, Rotterdam, the Netherlands (Dr de Feyter); and Hopital Bichat, Paris, France (Dr Vahanian).

RELATED ARTICLE

Should Bivalirudin Replace Heparin During Percutaneous Coronary Interventions?
Elliott M. Antman
JAMA. 2003;289(7):903-905.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of bivalirudin or unfractionated heparin on platelet aggregation in patients pretreated with 600 mg clopidogrel undergoing elective percutaneous coronary intervention
Sibbing et al.
Eur Heart J 2008;29:1504-1509.
ABSTRACT | FULL TEXT  

Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Schulman et al.
Chest 2008;133:257S-298S.
ABSTRACT | FULL TEXT  

Treatment and Prevention of Heparin-Induced Thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Warkentin et al.
Chest 2008;133:340S-380S.
ABSTRACT | FULL TEXT  

Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Harrington et al.
Chest 2008;133:670S-707S.
ABSTRACT | FULL TEXT  

Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Goodman et al.
Chest 2008;133:708S-775S.
ABSTRACT | FULL TEXT  

Bivalirudin during Primary PCI in Acute Myocardial Infarction
Stone et al.
NEJM 2008;358:2218-2230.
ABSTRACT | FULL TEXT  

Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative
Wang et al.
Eur Heart J 2008;29:1103-1109.
ABSTRACT | FULL TEXT  

Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention
Kereiakes and Gurbel
J Am Coll Cardiol Intv 2008;1:111-121.
ABSTRACT | FULL TEXT  

Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions Appropriateness of Including Bleeding as a Component of a Quadruple End Point.
Ndrepepa et al.
J Am Coll Cardiol 2008;51:690-697.
ABSTRACT | FULL TEXT  

Safety of carotid artery stenting for symptomatic carotid artery disease: a meta-analysis
Gurm et al.
Eur Heart J 2008;29:113-119.
ABSTRACT | FULL TEXT  

Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials
Dumaine et al.
Arch Intern Med 2007;167:2423-2430.
ABSTRACT | FULL TEXT  

Efficacy and Safety of Bivalirudin Versus Heparins in Reduction of Cardiac Outcomes in Acute Coronary Syndrome and Percutaneous Coronary Interventions
Singh et al.
J CARDIOVASC PHARMACOL THER 2007;12:283-291.
ABSTRACT  

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial
Mehta et al.
J Am Coll Cardiol 2007;50:1742-1751.
ABSTRACT | FULL TEXT  

Vascular Closure Devices: The Second Decade
Dauerman et al.
J Am Coll Cardiol 2007;50:1617-1626.
ABSTRACT | FULL TEXT  

Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia
Levy et al.
Anesth. Analg. 2007;105:570-582.
ABSTRACT | FULL TEXT  

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT  

Major bleeding after PCI. Where is our crystal ball?
Spencer and Steg
Eur Heart J 2007;28:1917-1919.
FULL TEXT  

Effects of Unfractionated Heparin and Glycoprotein IIb/IIIa Antagonists Versus Bivalirdin on Myeloperoxidase Release From Neutrophils
Li et al.
Arterioscler. Thromb. Vasc. Bio. 2007;27:1850-1856.
ABSTRACT | FULL TEXT  

Beyond Unfractionated Heparin and Warfarin: Current and Future Advances
Hirsh et al.
Circulation 2007;116:552-560.
FULL TEXT  

Timing of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes
Naina et al.
JAMA 2007;298:37-37.
FULL TEXT  

Timing of Glycoprotein IIb/IIIa Inhibitors in Acute Coronary Syndromes--Reply
Stone and for the ACUITY Investigators
JAMA 2007;298:37-38.
FULL TEXT  

Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2007;28:1598-1660.
FULL TEXT  

Recombinant Nematode Anticoagulant Protein c2 in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome: The ANTHEM-TIMI-32 Trial
Giugliano et al.
J Am Coll Cardiol 2007;49:2398-2407.
ABSTRACT | FULL TEXT  

Randomized, Double-Blind, Dose-Ranging Study of Otamixaban, a Novel, Parenteral, Short-Acting Direct Factor Xa Inhibitor, in Percutaneous Coronary Intervention: The SEPIA-PCI Trial
Cohen et al.
Circulation 2007;115:2642-2651.
ABSTRACT | FULL TEXT  

Acute Coronary Care in the Elderly, Part I: Non-ST-Segment-Elevation Acute Coronary Syndromes: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology
Alexander et al.
Circulation 2007;115:2549-2569.
ABSTRACT | FULL TEXT  

Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes
Rao et al.
Eur Heart J 2007;28:1193-1204.
ABSTRACT | FULL TEXT  

Anticoagulants in heart disease: current status and perspectives
De Caterina et al.
Eur Heart J 2007;0:ehl492v1-34.
FULL TEXT  

The economic burden of complications during percutaneous coronary intervention
Jacobson et al.
Qual Saf Health Care 2007;16:154-159.
ABSTRACT | FULL TEXT  

Impact of Major Bleeding on 30-Day Mortality and Clinical Outcomes in Patients With Acute Coronary Syndromes: An Analysis From the ACUITY Trial
Manoukian et al.
J Am Coll Cardiol 2007;49:1362-1368.
ABSTRACT | FULL TEXT  

Antithrombin treatment in patients with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention
Collet et al.
Eur Heart J Suppl 2007;9:A11-A24.
ABSTRACT | FULL TEXT  

Antiplatelet treatment in non-ST-segment elevation acute coronary syndrome patients undergoing percutaneous coronary intervention (ISAR-REACT 2 insight)
Dudek et al.
Eur Heart J Suppl 2007;9:A25-A31.
ABSTRACT | FULL TEXT  

Enoxaparin in elective percutaneous coronary intervention.
Bhala et al.
NEJM 2006;355:2788-2789.
FULL TEXT  

The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part I: Pathophysiology and Clinical Trial Evidence (Risk Factors Through Stable Coronary Artery Disease)
Dzau et al.
Circulation 2006;114:2850-2870.
FULL TEXT  

Drive-Through Angioplasty: Is It Safe or Necessary?
Mixon and Dehmer
Circulation 2006;114:2578-2580.
FULL TEXT  

A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation
Bertrand et al.
Circulation 2006;114:2636-2643.
ABSTRACT | FULL TEXT  

Bivalirudin for Patients with Acute Coronary Syndromes.
Stone et al.
NEJM 2006;355:2203-2216.
ABSTRACT | FULL TEXT  

Accounting for ACUITY.
Bittl
NEJM 2006;355:2249-2250.
FULL TEXT  

Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement
Hochholzer et al.
J Am Coll Cardiol 2006;48:1742-1750.
ABSTRACT | FULL TEXT  

Promotion of proinflammatory interactions between platelets and monocytes by unfractionated heparin
Harding et al.
Heart 2006;92:1635-1638.
ABSTRACT | FULL TEXT  

Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention.
Montalescot et al.
NEJM 2006;355:1006-1017.
ABSTRACT | FULL TEXT  

Risk of bleeding after elective percutaneous coronary intervention.
O'Neill
NEJM 2006;355:1058-1060.
FULL TEXT  

Bivalirudin Provides Rapid, Effective, and Reliable Anticoagulation During Off-Pump Coronary Revascularization: Results of the "EVOLUTION OFF" Trial.
Koster et al.
Anesth. Analg. 2006;103:540-544.
ABSTRACT | FULL TEXT  

Heparin-Induced Thrombocytopenia
Arepally and Ortel
NEJM 2006;355:809-817.
FULL TEXT  

Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
Kaul and Diamond
ANN INTERN MED 2006;145:62-69.
ABSTRACT | FULL TEXT  

Clinical end point definitions after percutaneous coronary intervention and their relationship to late mortality: an assessment by attributable risk
Chew et al.
Heart 2006;92:945-950.
ABSTRACT | FULL TEXT  

A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents: The PROTECT-TIMI-30 Trial
Gibson et al.
J Am Coll Cardiol 2006;47:2364-2373.
ABSTRACT | FULL TEXT  

The Future of an Illusion
Bittl
J Am Coll Cardiol 2006;47:2380-2383.
FULL TEXT  

Correlates of Bleeding Events Among Moderate- to High-Risk Patients Undergoing Percutaneous Coronary Intervention and Treated With Eptifibatide: Observations From the PROTECT-TIMI-30 Trial
Kirtane et al.
J Am Coll Cardiol 2006;47:2374-2379.
ABSTRACT | FULL TEXT  

Bivalirudin Anticoagulation for a Patient with Hypercoagulable Immune Syndromes Undergoing Mitral Valve Surgery
Cain et al.
Ann. Thorac. Surg. 2006;81:2308-2310.
ABSTRACT | FULL TEXT  

Abciximab in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment: The ISAR-REACT 2 Randomized Trial
Kastrati et al.
JAMA 2006;295:1531-1538.
ABSTRACT | FULL TEXT  

Reporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio et al.
JAMA 2006;295:1152-1160.
ABSTRACT | FULL TEXT  

Blocking the Protease-Activated Receptor 1-4 Heterodimer in Platelet-Mediated Thrombosis
Leger et al.
Circulation 2006;113:1244-1254.
ABSTRACT | FULL TEXT  

Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: The results of the EVOLUTION-OFF study.
J. Thorac. Cardiovasc. Surg. 2006;131:686-692.
 

The Value of Selectivity
Colombo and Stankovic
J Am Coll Cardiol 2006;47:719-720.
FULL TEXT  

Bivalirudin Use in Carotid Endarterectomy in a Patient with Heparin-Induced Thrombocytopenia
Finks
The Annals of Pharmacotherapy 2006;40:340-343.
ABSTRACT | FULL TEXT  

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
Smith et al.
J Am Coll Cardiol 2006;47:216-235.
FULL TEXT  

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)
Smith et al.
Circulation 2006;113:156-175.
FULL TEXT  

Reducing the Risk of Emergency Bypass Surgery for Failed Percutaneous Coronary Interventions
Bittl
J Am Coll Cardiol 2005;46:2010-2012.
FULL TEXT  

Peri-procedural myocardial injury: 2005 update
Herrmann
Eur Heart J 2005;26:2493-2519.
ABSTRACT | FULL TEXT  

Intracoronary Macrothrombus Formation During Percutaneous Coronary Intervention Despite Optimal Activated Clotting Time Using Bivalirudin: A Case Report
Tadros et al.
ANGIOLOGY 2005;56:761-765.
ABSTRACT  

Bivalirudin vs Heparin in Percutaneous Coronary Intervention: A Pooled Analysis
Ebrahimi et al.
J CARDIOVASC PHARMACOL THER 2005;10:209-216.
ABSTRACT  

Percutaneous Coronary Intervention-Related Bleeding Risk Factors in Current Practice
Mathis and Gugger
The Annals of Pharmacotherapy 2005;39:1627-1632.
ABSTRACT | FULL TEXT  

Direct Thrombin Inhibitors
Di Nisio et al.
NEJM 2005;353:1028-1040.
FULL TEXT  

Preventing in-hospital cardiac and renal complications in high-risk PCI patients
Brinker et al.
Eur Heart J Suppl 2005;7:G13-G24.
ABSTRACT | FULL TEXT  

Preemptive Use of Bivalirudin for Urgent On-Pump Coronary Artery Bypass Grafting in Patients With Potential Heparin-Induced Thrombocytopenia
Dyke et al.
Ann. Thorac. Surg. 2005;80:299-303.
ABSTRACT | FULL TEXT  

Use of Bivalirudin During Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: An Analysis From the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 Trial
Gurm et al.
J Am Coll Cardiol 2005;45:1932-1938.
ABSTRACT | FULL TEXT  

To Cath or Not to Cath: That Is No Longer the Question
Bhatt
JAMA 2005;293:2935-2937.
FULL TEXT  

Assessment of hemostatic activation during cardiopulmonary bypass for coronary artery bypass grafting with bivalirudin: Results of a pilot study
Koster et al.
J. Thorac. Cardiovasc. Surg. 2005;129:1391-1394.
ABSTRACT | FULL TEXT  

Anticoagulation Monitoring Part 1: Warfarin and Parenteral Direct Thrombin Inhibitors
Spinler et al.
The Annals of Pharmacotherapy 2005;39:1049-1055.
ABSTRACT | FULL TEXT  

Changing roles of anticoagulant and antiplatelet treatment during percutaneous coronary intervention
Kelly and Steinhubl
Heart 2005;91:iii16-iii19.
FULL TEXT  

Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study
Patti et al.
Circulation 2005;111:2099-2106.
ABSTRACT | FULL TEXT  

Gender Differences in Outcomes After Primary Angioplasty Versus Primary Stenting With and Without Abciximab for Acute Myocardial Infarction: Results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Lansky et al.
Circulation 2005;111:1611-1618.
ABSTRACT | FULL TEXT  

Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology
Authors/Task Force Members et al.
Eur Heart J 2005;26:804-847.
FULL TEXT  

What is the proper activated clotting time (ACT) at which to remove a femoral sheath after PCI? What are the best "protocols" for sheath removal?
Galli and Palatnik
Crit Care Nurse 2005;25:88-5.
FULL TEXT  

Potent inhibition of thrombin with a monoclonal antibody against tissue factor (Sunol-cH36): results of the PROXIMATE-TIMI 27 trial
Morrow et al.
Eur Heart J 2005;26:682-688.
ABSTRACT | FULL TEXT  

Percutaneous Coronary Intervention and Adjunctive Pharmacotherapy in Women: A Statement for Healthcare Professionals From the American Heart Association
Lansky et al.
Circulation 2005;111:940-953.
ABSTRACT | FULL TEXT  

Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices
Farouque et al.
J Am Coll Cardiol 2005;45:363-368.
ABSTRACT | FULL TEXT  

Thrombocytopenia in Cardiovascular Patients: Diagnosis and Management
Matthai
Chest 2005;127:46S-52S.
ABSTRACT | FULL TEXT  

New anticoagulants
Hirsh et al.
Blood 2005;105:453-463.
ABSTRACT | FULL TEXT  

Randomized Clinical Trial of Abciximab in Diabetic Patients Undergoing Elective Percutaneous Coronary Interventions After Treatment With a High Loading Dose of Clopidogrel
Mehilli et al.
Circulation 2004;110:3627-3635.
ABSTRACT | FULL TEXT  

Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial
Cohen et al.
J Am Coll Cardiol 2004;44:1792-1800.
ABSTRACT | FULL TEXT  

Economic impact of new interventional therapies: Are we asking the right questions?
Kong and Mark
J Am Coll Cardiol 2004;44:1809-1811.
FULL TEXT